GILEAD SCIENCES, INC. Proceeds from Convertible Debt
GILEAD SCIENCES, INC. (GILD) reported Proceeds from Convertible Debt of $0 for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-23.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2012-02-23
- GILEAD SCIENCES, INC. proceeds from convertible debt for the quarter ending 2010-12-31 was $0.00.
- GILEAD SCIENCES, INC. proceeds from convertible debt for the quarter ending 2009-12-31 was $0.00.
- GILEAD SCIENCES, INC. proceeds from convertible debt for fiscal 2011 was $0.00, a 100.00% decline from fiscal 2010.
- GILEAD SCIENCES, INC. proceeds from convertible debt for fiscal 2010 was $2.46B.
- GILEAD SCIENCES, INC. proceeds from convertible debt for fiscal 2009 was $0.00.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|
| 2011-12-31 | $0.00 10-K · filed 2012-02-23 | ||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $2.46B 10-K · filed 2012-02-23 | |
| 2010-09-30 | $2.46B 10-Q · filed 2011-11-04 | ||
| 2009-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $0.00 10-K · filed 2012-02-23 | |
| 2009-09-30 | $0.00 10-Q · filed 2010-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |